- US-listed companies
- Kezar Life Sciences, Inc.
- Income statement
Kezar Life Sciences, Inc.KZR
Market cap
$45.73M
P/E ratio
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | - | - | - | - | 7 | - |
| Research & development | 18 | 27 | 31 | 39 | 51 | 86 | 66 |
| Operating margin (%) | - | - | - | - | - | - | |
| Operating income | -25 | -37 | -43 | -55 | -71 | -111 | -91 |
| Operating expenses | 25 | 37 | 43 | 55 | 71 | 118 | 91 |
| Net income | -23 | -35 | -42 | -55 | -68 | -102 | -84 |
| Net income margin (%) | - | - | - | - | - | - | |
| Earnings per share | - | - | - | - | -1.01 | -1.4 | -11.49 |
| Diluted EPS | - | - | - | - | -1.01 | -1.4 | -11.49 |
| EBITDA | |||||||
| EBITDA margin (%) | - | - | - | - | - | - |